Company Filing History:
Years Active: 2007-2019
Title: Annemieke M De Jong: Innovator in Immunology
Introduction
Annemieke M De Jong is a prominent inventor based in Amsterdam, Netherlands. She has made significant contributions to the field of immunology, particularly in the development of peptide-based vaccines. With a total of 4 patents to her name, her work focuses on enhancing immune responses against various infections and cancers.
Latest Patents
One of her latest patents involves long peptides of 22-45 amino acid residues that induce and enhance antigen-specific immune responses. This patent discloses epitopes derived from the human papilloma virus (HPV) and peptides that comprise minimal T cell epitopes. The research highlights clinically relevant approaches for immunizing subjects against mycobacterial and viral infections, as well as tumor cells. Notably, peptide sequences of 22-35 amino acid residues can induce both CD8+ cytolytic cells and CD4+ T-helper cells. Furthermore, vaccination with these longer peptides results in a more vigorous CD8+ cytolytic T-cell response compared to shorter peptides. The patent also addresses the challenges posed by certain minimal CTL epitopes that can tolerize cytolytic cells, offering solutions through the use of 22-35 amino acid long peptides. This work is crucial for developing vaccines and treatments for subjects suffering from progressive lesions and cervical cancer.
Career Highlights
Annemieke M De Jong is affiliated with Academisch Ziekenhuis Leiden, where she continues her research and innovation in immunology. Her work has garnered attention for its potential impact on vaccine development and cancer treatment.
Collaborations
She collaborates with notable colleagues, including Sjoerd Hendrikus Van Der Burg and Annemieke Geluk, contributing to a dynamic research environment focused on advancing immunological therapies.
Conclusion
Annemieke M De Jong is a leading figure in the field of immunology, with a focus on peptide-based vaccines that enhance immune responses. Her innovative work has the potential to significantly impact the treatment of infections and cancers.